Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings

$3M USD

Funder	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Recipient Organization	Salus Discovery, Llc
Country	United States
Start Date	Jul 10, 2024
End Date	Jun 30, 2025
Duration	355 days
Number of Grantees	2
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`11006515`

Grant Description

ABSTRACT Mycobacterium tuberculosis (TB) is a global threat to human health and accounts for 20% of adult deaths in low- income countries (~1.6 million deaths/year), yet only ~23% of new TB patients receive a WHO recommended nucleic acid test, while 37% receive tests with significantly lower sensitivity (e.g., smear microscopy), and ~40%

cases do not have access to testing. The critical gap in TB diagnostics, and the weakest link in global TB care, is access to high-quality TB testing. In order to address this, the WHO has developed target product profiles for the highest-priority TB diagnostic technologies and key among them is an affordable (